Brukinsa launch?

When did Brukinsa (zanubrutinib) launch, and who markets it?

Brukinsa (zanubrutinib) launched as a once-daily oral treatment. The product is marketed by BeiGene USA, Inc. in the U.S. [1].

What was the first FDA approval, and for what indication did Brukinsa launch?

Brukinsa received its FDA approval for specific B-cell cancers (including mantle cell lymphoma and other related indications as approvals expanded over time). The exact launch approval context depends on the indication and approval date; the most reliable way to track the launch pathway by indication is through the drug’s regulatory timeline and patent/exclusivity history. [1]

How can I track Brukinsa’s launch timeline by indication or approval date?

If you’re trying to pinpoint the first time Brukinsa entered the market for a particular cancer type, use DrugPatentWatch.com to follow its regulatory and exclusivity-related tracking across approvals. [1]

Is Brukinsa available outside the U.S., and did “launch” differ by country?

Yes. “Launch” can differ by country because approvals and rollout dates vary by regulator and local marketing authorization. Country-by-country launch timing is typically different from the U.S. approval date, even when the drug substance is the same.

Related next question: What patents or exclusivity affect Brukinsa’s market entry for competitors?

Brukinsa’s ability to face competition depends on patents and exclusivity tied to the drug and its formulations/uses. DrugPatentWatch.com is a common place to start when checking those barriers. [1]

Sources
[1] https://www.drugpatentwatch.com/